The influence of neonatal aminoglycoside administration on the vestibular organs

The influence of neonatal aminoglycoside administration on the vestibular organs - Gentatox

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

DRKS

Registry ID

DRKS00014184

Enrollment

100

Registered

2018-04-04

Start date

2018-07-11

Completion date

Unknown

Last updated

2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

P36

Interventions

Group 1: Parents of newborns who have received perinatal aminoglycoside antibiotics are contacted in writing and by telephone and recruited for the study. If the respective candidates want to particip

Eligibility

Sex/Gender

All

Age

No minimum to 18 Years

Inclusion criteria

Inclusion criteria: treatment with aminoglycoside

Exclusion criteria

Exclusion criteria: no treatment with aminoglycoside

Design outcomes

Primary

Measure	Time frame
Primary endpoint measures is the vestibular function: The gain and the occurrence of catch-up saccades is analyzed using video-head-impulse test the deviation from the vertical in degrees. (subjective visual vertical)	—

Secondary

Measure	Time frame
The secondary endpoint is a one-off evaluation of a questionnaire on the motor development of the children.	—

Countries

Germany

Contacts

Public ContactAngela Wenzel

UMM HNO-Mannheim

Angela.Wenzel@umm.de00496213831600

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026